Volume 4, Issue 8
Editorialp. 675–677
A focus on translational medicine is necessary to close the innovation gap in pharmaceutical medicine
Author(s): Andreas WallnOfer
Editorialp. 679–681
Clinical progress for enterovirus 71 vaccines: what does the future hold?
Author(s): Jing-Xin Li, Feng-Cai Zhu
Editorialp. 683–685
The challenges of dengue drug discovery and development
Author(s): Feng Gu, Pei-Yong Shi
Research Updatep. 687–691
How dementia and neurodegenerative disease clinical research networks have enhanced research delivery in England
Author(s): Piers Kotting, Martin N Rossor, Ian G McKeith & John T OBrien
Clinical Trail Methodologyp. 693–704
Two decades testing interventions in transgenic mouse models of Alzheimers disease: designing and interpreting studies for clinical trial success
Author(s): Kieren Egan, & Malcolm Macleod
Clinical Trail Outcomesp. 705–728
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Author(s): Edward L Nelson
Clinical Trail Outcomesp. 729–743
Dulaglutide: a novel once-weekly glucagon-like peptide-1 receptor agonist
Author(s): Signe V Naver, Espen Jimenez-Solem, Mikkel Christensen, Jon T Andersen & Filip K Knop
Clinical Trail Outcomesp. 745–761
Recent clinical evidence for topical mechlorethamine in mycosis fungoides
Author(s): Joya Sahu, Marjan Sepassi, Mitchell Nagao & Youn H Kim
Review Articlep. 763–773
Alitretinoin for the treatment of chronic hand eczema: clinical rationale
Author(s): Vivian Y Shi, Raja K Sivamani & Howard Maibach
